Health care resource use, productivity, and costs among patients with moderate to severe plaque psoriasis in the United States - 14/09/15
, Joseph C. Cappelleri, PhD c, Rebecca Cheng, PharmD, MS b, Jason C. Cole, PhD b, Scott Guenthner, MD d, Joseph Fowler, MD e, Sandy Johnson, MD f, Carla Mamolo, PhD cAbstract |
Background |
Comprehensive studies on costs of moderate to severe plaque psoriasis (MSPP) have not been conducted in the United States.
Objective |
We sought to evaluate current health care resource use, productivity, and costs among patients with MSPP in routine practice.
Methods |
A total of 200 adults seeking MSPP treatment enrolled in 9 US sites. Consented patients reported symptoms, treatment, lost productivity, and costs; 6-month retrospective chart review captured health care resource use and clinical characteristics. Costs were assigned to health care resource use and lost productivity using standard algorithms. Differences by Psoriasis Area and Severity Index (PASI) group, based on PASI score (≤10, >10-≤20, >20) at enrollment, were evaluated. Analyses included descriptive statistics and analysis of variance or Kruskal-Wallis tests.
Results |
Most patients (79.5%) were prescribed 1 or more MSPP medications (mean: 1.5); 36.0% and 9.0% received self-administered biologics and systemic therapies, respectively. Mean number of nonprescription treatments was 12.3. Differences by PASI group were observed for overall work and activity impairment (P < .02). Six-month total MSPP direct costs per patient were $11,291; indirect costs were $2101 and differed across PASI groups (P = .0008).
Limitations |
This study enrolled patients with MSPP actively seeking care.
Conclusion |
Despite treatment, a number of patients with MSPP continue to experience moderate to severe PASI scores, impaired functioning, and high costs suggesting a need for new treatment options.
Le texte complet de cet article est disponible en PDF.Key words : burden of illness, chart review, costs, economic burden, health care resource use, moderate to severe plaque psoriasis, observational research, productivity
Abbreviations used : BSA, CDC, HCRU, MSPP, PASI
Plan
| This research was supported by Pfizer. |
|
| Disclosure: Dr Cheng and Ms Schaefer are employees of Covance Market Access Services Inc, which was paid by Pfizer to design and execute this study and to develop this manuscript. Dr Cole was an employee of Covance Market Access Services Inc at the time of the study; currently, Dr Cole is an employee of Pharmaceutical Product Development LLC. Dr Cappelleri and Dr Mamolo are employees of Pfizer. Dr Fowler, Dr Guenthner, and Dr Johnson were paid investigators for the study; they were not financially compensated for collaborative efforts on publication-related activities. |
|
| Reprints not available from the authors. |
Vol 73 - N° 4
P. 585 - octobre 2015 Retour au numéro
Article précédent
- Answers to CME examination
- Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study
- Ian Landells, Colleen Marano, Ming-Chun Hsu, Shu Li, Yaowei Zhu, Lawrence F. Eichenfield, Peter H. Hoeger, Alan Menter, Amy S. Paller, Alain Taieb, Sandra Philipp, Philippe Szapary, Bruce Randazzo
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?